Early research (Phase 1)Not Yet RecruitingNCT06623279
What this trial is testing
Open-laBel Dose-escalation Study for CRISPR/cas13- Rna TargetInG THerapy for the Treatment of Neovascular Age-related Macular Degeneration in Phase I Trial
Who this might be right for
Neovascular Age-Related Macular Degeneration (nAMD)
HuidaGene Therapeutics Co., Ltd. 15